K.N.V. Pharmacy College-Metoda, Rajkot, Gujarat, India.
J Pharm Pharmacol. 2010 May;62(5):610-4. doi: 10.1211/jpp.62.05.0008.
Our aim was to investigate the effect of etoricoxib on the anticonvulsant activity of phenytoin and diazepam against seizure models in mice. In addition the acute adverse effect of etoricoxib was assessed with a chimney test.
The maximal seizure pattern was induced in mice by giving an alternating current of 50 mA for 0.2 s, while chemical seizures were induced by intraperitoneal injection of pentylenetetrazole at its CD97 dose (97% convulsive dose for the clonic phase). Test drug was administered 45 min before the electrical or chemical induction of seizures in combination with conventional antiepileptics. The ability of the test drug to reduce or abolish the extensor phase of maximal electroshock and clonic-type seizures in the chemical induction method was selected as anti-seizure criteria.
Concurrent treatment with etoricoxib at an oral dose of 10 mg/kg reduced the anticonvulsant potency of phenytoin. The protective effects of diazepam against pentylenetetrazole-induced convulsions was significantly increased and the mortality rate was reduced by concurrent treatment with etoricoxib (10 mg/kg p.o.) when compared with diazepam groups. No neurotoxic effect was observed with etoricoxib (10 mg/kg p.o.) and it had no impact on motor coordination in the chimney test in mice. Etoricoxib applied at its highest dose (10 mg/kg) significantly enhanced the free plasma levels of diazepam whereas the free plasma levels of phenytoin were significantly reduced.
The obtained results suggest that the preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduced the anticonvulsant action of phenytoin and significantly increased the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model.
我们旨在研究依托考昔对苯妥英和地西泮抗惊厥活性的影响,以及依托考昔对小鼠惊厥模型的急性不良反应。
通过给予 50 mA 的交流电 0.2 s 来诱导最大惊厥模式,同时通过腹腔注射戊四氮诱导化学惊厥,达到其 CD97 剂量(戊四氮致阵挛相的 97%惊厥剂量)。在电或化学诱导惊厥之前 45 分钟给予测试药物,与常规抗癫痫药联合使用。选择测试药物减少或消除最大电休克和化学诱导方法中强直相的能力作为抗惊厥标准。
依托考昔(口服剂量为 10mg/kg)的同时治疗降低了苯妥英的抗惊厥效力。与地西泮组相比,依托考昔(10mg/kg,po)的同时治疗显著增加了地西泮对戊四氮诱导惊厥的保护作用,并降低了死亡率。依托考昔(10mg/kg,po)无神经毒性作用,且在小鼠烟囱试验中对运动协调无影响。依托考昔(10mg/kg)最高剂量显著增加了地西泮的游离血浆水平,而苯妥英的游离血浆水平则显著降低。
研究结果表明,选择性环氧化酶-2 抑制剂依托考昔显著降低了苯妥英的抗惊厥作用,显著增加了地西泮对最大电休克和戊四氮诱导惊厥的有益作用。